Last reviewed · How we verify
AGN-190584 ophthalmic solution
AGN-190584 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.
AGN-190584 ophthalmic solution is a corticosteroid used to treat inflammation in the eye. Used for Treatment of inflammation and pain in the eye.
At a glance
| Generic name | AGN-190584 ophthalmic solution |
|---|---|
| Sponsor | Allergan |
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
AGN-190584 ophthalmic solution works by suppressing the immune system's response to inflammation in the eye, thereby reducing swelling and pain. This is achieved through the inhibition of phospholipase A2, a key enzyme involved in the inflammatory process. By reducing inflammation, AGN-190584 ophthalmic solution helps to promote healing and reduce discomfort in the affected eye.
Approved indications
- Treatment of inflammation and pain in the eye
Common side effects
- Eye irritation
- Blurred vision
- Eye dryness
Key clinical trials
- A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age (PHASE3)
- A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily (PHASE3)
- Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia (PHASE2)
- A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia (PHASE3)
- Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia (PHASE3)
- A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia (PHASE2)
- A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia (PHASE2)
- Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGN-190584 ophthalmic solution CI brief — competitive landscape report
- AGN-190584 ophthalmic solution updates RSS · CI watch RSS
- Allergan portfolio CI